CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ — Biobot Analytics, the leader in wastewater intelligence, today announced a new round of funding led by Valor Equity Partners. Alongside Valor, Biobot is also welcoming new investor Atreides Management, as well as participation from existing investors, including Hyperplane. The investment reflects strong ongoing support for Biobot’s mission to build a wastewater intelligence platform for healthcare and national security applications.
The capital will support the company’s expanding suite of wastewater intelligence offerings, enabling continued innovation in advanced analytics, product development, and partnerships across government and commercial sectors.
As part of this round, Biobot is pleased to welcome new board members:
They join Biobot’s cofounders and existing Board Directors, Dr. Mariana Matus and Newsha Ghaeli, in guiding the company’s long-term strategy.
“We are proud to be backed by some of the most forward-thinking investors in the tech industry,” said Dr. Mariana Matus, CEO of Biobot Analytics. “Their support and insight will be instrumental as we build a new category of health intelligence—using wastewater data to create a safer, healthier, and more resilient society.”
“Biobot is a category-defining company with a bold vision for the future of healthcare and biosecurity,” said Vivek Pattipati, Partner at Valor Equity Partners. “We’re excited to support the talented team at Biobot as they bring innovative new products to market.”
Founded at the Massachusetts Institute of Technology, Biobot Analytics pioneered wastewater-based epidemiology in cities. From tracking COVID-19 trends across hundreds of communities to detecting opioid use and other health indicators, Biobot’s technology empowers governments and organizations with critical data.
About Biobot Analytics
Biobot Analytics is the global leader in wastewater intelligence. By analyzing wastewater, Biobot delivers real-time, community-wide insights into population health, empowering governments and organizations to identify outbreaks, monitor behavioral trends, and prepare for emerging threats. Learn more at www.biobot.io.
SOURCE Biobot Analytics, Inc.
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…